The Patentability of Business Methods - a Global Perspective
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Patent Law: a Handbook for Congress
Patent Law: A Handbook for Congress September 16, 2020 Congressional Research Service https://crsreports.congress.gov R46525 SUMMARY R46525 Patent Law: A Handbook for Congress September 16, 2020 A patent gives its owner the exclusive right to make, use, import, sell, or offer for sale the invention covered by the patent. The patent system has long been viewed as important to Kevin T. Richards encouraging American innovation by providing an incentive for inventors to create. Without a Legislative Attorney patent system, the reasoning goes, there would be little incentive for invention because anyone could freely copy the inventor’s innovation. Congressional action in recent years has underscored the importance of the patent system, including a major revision to the patent laws in 2011 in the form of the Leahy-Smith America Invents Act. Congress has also demonstrated an interest in patents and pharmaceutical pricing; the types of inventions that may be patented (also referred to as “patentable subject matter”); and the potential impact of patents on a vaccine for COVID-19. As patent law continues to be an area of congressional interest, this report provides background and descriptions of several key patent law doctrines. The report first describes the various parts of a patent, including the specification (which describes the invention) and the claims (which set out the legal boundaries of the patent owner’s exclusive rights). Next, the report provides detail on the basic doctrines governing patentability, enforcement, and patent validity. For patentability, the report details the various requirements that must be met before a patent is allowed to issue. -
"Reasonably" Compensate Employee Invento Rs in Japan
By Calvin GRIFFITH, MICHIRU Takahashi & Nobutaka KOMIyAMA bly" Compe ona nsat as e E "Re m o pl t o g ye n e i il In a v F e f n o t o s r l s l i a n f J t i a P p a e N h : T EMPLOYERS BEWARE The United States is generally considered a more litigious paying seven-figure sums in compensation for employee country than Japan, where customs traditionally favor a less inventions, having expected that the compensation provided confrontational approach to dispute resolution. But there is in the ordinary employment contract or internal employment one exception—employee invention lawsuits. A recent series regulations would be accepted by courts as reasonable. of lawsuits filed by aggrieved employee inventors against This stunning development in Japanese courts is based on their employer companies, demanding “reasonable remu- Japan’s unique employee invention system under Article neration” for the employees’ inventions, has brought atten- 35 of the Japan Patent Law, and foreign companies doing tion to this unique area of Japanese patent law—and raised business in Japan, especially those with R&D facilities there, concern in the business community. Japanese companies should be familiar with the provisions of Article 35 and the were shocked to find themselves facing the possibility of case law applying it. 14 orIgIn oF thE FUss—ArtIclE 35 AnD thE olyMPUs CasE be entitled to remuneration based on income from the pat- Article 35 of the Japan Patent law. Japan has a unique ents. Pursuant to those regulations, Olympus acquired a pat- employee invention system under Article 35 of the Patent ent on employee Tanaka’s invention. -
The Benefits of Japanese Patent Law System Over Those of the US in the Pharmaceutical Area
The Benefits of Japanese Patent Law System Over those of the US in the Pharmaceutical Area What can we do to maximize the benefits? William Han (GlaxoSmithKline) Japan Patent Attorneys Association International Activities Center 1 “Long Long Time Ago” • Poor Prosecution • Slow, Claim scope narrow if granted at all, claim types not sufficient • Weak Enforcement • Court proceedings took forever; Infringement/damages hard to prove; Damages minimal Regarding Enforcement: October 1994 – US Commissioner of Patents Bruce Lehman: “…the relative nonlitigiousness of Japanese society tends to minimize the importance of enforcement...US citizens holding Japanese patents should be able to rely on those patents more than their US patents…” Circa late 1990’s, JPO Commissioner Tekashi Isayama admitted: “The Japanese market is dishonorably regarded as ‘lenient towards infringement’. It is sometimes said that one may as well infringe whatever patents he likes in Japan, because court proceedings are slow and compensation insignificant” (taken from Mr Shusaku Yamamoto’s post) 2 • Aging population and attendant increase in healthcare cost, Japanese government started to aggressively promote the use of generic drug since 2007 • More numbers: • Sept 2016 – about 60% (by volume) • Japanese government wants to increase the use to 80% in fiscal year 2018-2020! • Patents are the only effective tools available to prevent the entry of generics 3 • Unlike in prior to 2007, opportunity cost of “not getting things right” in Japan could be enormous Comparison Between US v Japanese Patent Term Extension System • Both in Japan and US, if a drug undergoes clinical trial and review period, the patent which covers the drug can be extended up to 5 years. -
Best Mode Disclosure for Patent Applications: an International and Comparative Perspective
Journal of Intellectual Property Rights Vol 16, September 2011, pp 409-417 Best Mode Disclosure for Patent Applications: An International and Comparative Perspective Bingbin Lu† Nanjing University Law School, No 22, Hankou Road, Nanjing, 210 093, China Received 13 June 2011, revised 13 July 2011 The best mode disclosure requirement helps to ensure that the public receives a full and honest disclosure in return for the grant of patent. It has a profound theoretical basis and foundation. The best mode disclosure requirement is an optional obligation under the TRIPS Agreement in its Article 29. Among the most important developed countries that have implemented this disclosure requirement are the US and Japan; however, there are certain differences in their national laws and practices, especially with regard to the legal effect of this requirement. In the US, patent reform is tending towards removing the best mode disclosure from the list of reasons to invalidate a granted patent; although, the requirement will still apply to all patent applications during patent prosecutions. Developing countries are recommended to consider adopting the best mode disclosure requirement in their patent laws. It is proposed that patent applicants be required to disclose the best mode which shall be a substantive condition for patent grant; however, the failure to disclose the best mode may not constitute a reason to invalidate a granted patent. The objective of this article is to study the best mode disclosure requirement from an international and comparative perspective, and suggest how developing countries should implement this disclosure requirement. The article also seeks to answer to two questions: whether a developing country should implement the best mode disclosure requirement, and if so, how to best implement it? Keywords: Patent, best mode, disclosure requirements, TRIPS Agreement Disclosure is one of the key issues in the patent requirement is the first paragraph of Section 112, Title system. -
Life Sciences & Biotechnology Legal Bulletin
ISSUE 29 | FEBRUARY 16, 2012 LIFE SCIENCES & BIOTECHNOLOGY LEGAL BULLETIN SCIENCE • TECHNOLOGY ENGINEERING • ENERGY PHARMACEUTICAL CONTENTS IP NEWS IP News USPTO Proposes New Rules of Trial and Appellate Practice Under AIA ...........1 USPTO Proposes New Rules of Trial and Appellate Practice Under AIA Investor News The U.S. Patent and Trademark Office (USPTO) has issued proposed rules of Massachusetts Biotech Adds $6.3 Million practice to implement sections of the America Invents Act (AIA) that provide Targeted to Stem Cell Reagents .........2 for trials before the Patent Trial and Appeal Board and address judicial review of Biopharmaceutical Secures $2.2 Million to Develop Pancreatic Cancer Vaccine ...2 board decisions. Comments are requested by April 9, 2012. Business Climate According to USPTO’s notice, “the proposed rules would provide a consolidated Life Sciences Startups Generate More Capital in 2011, Biotech Job Ads Down set of rules relating to Board trial practice for inter partes review, post-grant Slightly in Q4 ...........................2 review, derivation proceedings, and the transitional program for covered Companion Diagnostics in Personalized business method patents by adding a new part 42 including a new subpart A Medicine Facing Explosive Growth ......3 to title 37 of the Code of Federal Regulations. The proposed rules would also Indian Official Calls for Passage of Biotech Regulatory Legislation and provide a consolidated set of rules to implement the provisions of the Leahy- Increased VC Funding. 3 Smith America Invents Act related to seeking judicial review of Board decisions Legislative and Regulatory Developments by adding a new part 90 to title 37 of the Code of Federal Regulations.” Separate FDA Issues Draft Biosimilars Guidance, rulemakings address proposed rules specific to inter partes review, post-grant Gaps Leave Practitioners Wondering ....4 review, the transitional program for covered business method patents, and Pay-for-Delay Deals and Biologics’ Exclusivity Period Part of President’s derivation proceedings. -
Can I Challenge My Competitor's Patent?
Check out Derek Fahey's new firm's website! CLICK HERE Can I Challenge My Competitor’s Patent? Yes, you can challenge a patent or patent publication. Before challenging a patent or patent publication, an analysis should be conducted by a registered patent attorney to determine if challenging a patent or patent publication is necessary, and to evaluate the legal grounds for challenging the patent or patent publication. As a registered patent attorney, I evaluate patents and patent applications to determine the risk of developing competing goods. Below are three important questions that must be answered by a registered patent attorney to evaluate the risk of competing against a patented good. 1. Does a particular good infringe on a patent? Typically, a registered patent attorney will conduct a “freedom to operate” opinion to determine if a business owner can commercialize a particular good without infringing on another’s patent. First, a patent attorney will determine if the patent is enforceable. Next, a patent attorney will perform an infringement analysis to determine if a particular good infringes on any of a patent’s claims. To perform an infringement analysis of a patent and a possibly infringing product, first, the patent’s scope must be analyzed. Second, the patent’s claim terms must be interrupted using the specification, prosecution history and extrinsic evidence to understand and construe the meaning of the claim terms. After the claim terms have been construed, then the elements of a particular good must be analyzed to determine if the particular good practices each and every claim element taught by a patent’s claim. -
Business Method Patents and Patent Floods
Washington University Journal of Law & Policy Volume 8 Symposium on Intellectual Property, Digital Technology & Electronic Commerce January 2002 Business Method Patents and Patent Floods Michael J. Meurer Boston University School of Law Follow this and additional works at: https://openscholarship.wustl.edu/law_journal_law_policy Part of the Intellectual Property Law Commons Recommended Citation Michael J. Meurer, Business Method Patents and Patent Floods, 8 WASH. U. J. L. & POL’Y 309 (2002), https://openscholarship.wustl.edu/law_journal_law_policy/vol8/iss1/12 This Patents and Bioinformatics - Essay is brought to you for free and open access by the Law School at Washington University Open Scholarship. It has been accepted for inclusion in Washington University Journal of Law & Policy by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. Business Method Patents and Patent Floods Michael J. Meurer* “[O]ne of the great inventions of our times, the diaper service [is not patentable].”1 Giles S. Rich “We take this opportunity to lay this ill-conceived exception to rest.”2 Giles S. Rich I. INTRODUCTION The decline of the business method exception to patentability will increase the frequency of patent floods. By patent flood, I mean a dramatic jump in the number of patents filed covering a specific class of inventions, as we now observe in e-commerce.3 Floods are likely to become more frequent as future entrepreneurs respond to the appearance of a new market with a spate of business method patent applications claiming new methods tailored to the new market. A flood of related patents in a new market creates special problems for competition in addition to the usual problems that arise * Associate Professor of Law, Boston University School of Law. -
Do Fixed Patent Terms Distort Innovation? Evidence from Cancer Clinical Trials
NBER WORKING PAPER SERIES DO FIXED PATENT TERMS DISTORT INNOVATION? EVIDENCE FROM CANCER CLINICAL TRIALS Eric Budish Benjamin N. Roin Heidi Williams Working Paper 19430 http://www.nber.org/papers/w19430 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 September 2013 Financial support from NIA Grant Number T32-AG000186 to the NBER, NSF Grant Number 1151497, the Chicago Booth Initiative on Global Markets, the NBER Innovation Policy and the Economy program, and the Petrie-Flom Center at Harvard Law School is gratefully acknowledged. We thank Meru Bhanot, David Burk, Toby Chaiken, Brian Cordonnier, Greg Howard, Niels Joaquin, Megan McGrath, and Ana Medrano-Fernandez for excellent research assistance. Daron Acemoglu, David Autor, Raj Chetty, Joe Doyle, Dan Fetter, Amy Finkelstein, Ray Fisman, Alberto Galasso, Amanda Kowalski, Anup Malani, Matt Notowidigdo, Felix Oberholzer-Gee, Ariel Pakes, Al Roth, Jon Skinner, Alan Sorensen, Scott Stern, Glen Weyl, and seminar participants at BEA, Carnegie Mellon, the CBO, the Cornell Empirical Patent Law Conference, Georgia Tech, Harvard Law School, MIT, the NBER (Industrial Organization, Law and Economics, Productivity, and Public Economics), the Northwestern Kellogg Healthcare Markets conference, Toulouse, UC-Berkeley Haas, UIUC, UVA, Wellesley, and Yale Law School provided very helpful comments. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. NBER working papers are circulated for discussion and comment purposes. They have not been peer- reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications. © 2013 by Eric Budish, Benjamin N. -
Of Japanese Patent Prosecution
The ‘Endless Loop’ of Japanese Patent Prosecution By Samson Helfgott and Paula E. Hopkins Katten Muchin Rosenman LLP First published in the May 2006 issue of World Intellectual Property Report Commentary The ‘Endless Loop’ of Japanese Patent Prosecution By Samson Helfgott and Paula E.Hopkins.Samson Helfgott During the course of the appeal trial, the Trial Examiners are is a Partner and Director of Patents, and Paula E. Hopkins is allowed to find a new reason and/or new prior art to reject the an associate in the IP Department of Katten Muchin patent application other than those stipulated in the decision of the Rosenman LLP, New York. The authors can be contacted examiner (Section 150, subsection 1 and Section 153, subsection by e-mail at: [email protected] and 1). In such case, the Board has to notify the new reason and/or [email protected] prior art to the applicant and allow the applicant to make counter-arguments against that reason and/or prior art before Patent prosecution in any patent system has its normal course of issuance of the decision of the Board (Section 159, subsection 2 delays. In significant cases, especially when broad claims are and Section 50). Accordingly, by way of example, although the being prosecuted, even more time may be required until a examiner may have only rejected the claim based upon certain resolution of the patent issues is reached. However, within the sections, such as lack of novelty, the Board of Trial Examiners can Japanese Patent System peculiarities within the law make such reject those claims for other reasons, such as indefiniteness, lack delays indefinite, resulting in an “endless loop” of prosecution of support, etc. -
Are Business Method Patents Bad for Business? Rochelle Dreyfuss
Santa Clara High Technology Law Journal Volume 16 | Issue 2 Article 3 January 2000 Are Business Method Patents Bad for Business? Rochelle Dreyfuss Follow this and additional works at: http://digitalcommons.law.scu.edu/chtlj Part of the Law Commons Recommended Citation Rochelle Dreyfuss, Are Business Method Patents Bad for Business?, 16 Santa Clara High Tech. L.J. 263 (2000). Available at: http://digitalcommons.law.scu.edu/chtlj/vol16/iss2/3 This Article is brought to you for free and open access by the Journals at Santa Clara Law Digital Commons. It has been accepted for inclusion in Santa Clara High Technology Law Journal by an authorized administrator of Santa Clara Law Digital Commons. For more information, please contact [email protected]. ESSAY ARE BUSINESS METHOD PATENTS BAD FOR BUSINESS? Rochelle Cooper Dreyfuss' TABLE OF CONTENTS I. State Street .................................................................................. 265 II. Implications of Business Method Patenting .................................. 267 A . Q uality ........................................................................................ 267 B . W isdom ...................................................................................... 274 m. Where to Go from Here ............................................................... 277 IV . Conclusion .................................................................................. 280 This is an exciting time at which to be involved in intellectual property. When I began teaching, this field was something of a backwater. Around thirty people took my introductory course; only seven went on to study patent law. Indeed, patent law was so esoteric, practitioners were historically among the very few lawyers ethically permitted to advertise their specialty.! In the last decade, however, all of that has changed. Not only are there many more students, what is really interesting as is the level of attention that this field is now receiving from Congress and the courts. -
Transitional Program for Covered Business Method Patents - Definitions Of
[3510-16-P] DEPARTMENT OF COMMERCE Patent and Trademark Office 37 CFR Part 42 [Docket No. PTO-P-2011-0087] RIN 0651-AC75 Transitional Program for Covered Business Method Patents - Definitions of Covered Business Method Patent and Technological Invention AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Final rule. SUMMARY: The United States Patent and Trademark Office (Office or USPTO) is revising the rules of practice to implement the provision of the Leahy-Smith America Invents Act (“AIA”) that requires the Office to issue regulations for determining whether a patent is for a technological invention in a transitional post-grant review proceeding for covered business method patents. The provision of the AIA will take effect on September 16, 2012, one year after the date of enactment. The AIA provides that this 1 provision and any regulations issued under the provision will be repealed on September 16, 2020, with respect to any new petitions under the transitional program. DATES: Effective Date: The changes in this final rule take effect on September 16, 2012. Applicability Date: The changes in this final rule apply to any covered business method patent issued before, on, or after September 16, 2012. FOR FURTHER INFORMATION CONTACT: Sally C. Medley, Administrative Patent Judge; Michael P. Tierney, Lead Administrative Patent Judge; Robert A. Clarke, Administrative Patent Judge; and Joni Y. Chang, Administrative Patent Judge; Board of Patent Appeals and Interferences, by telephone at (571) 272-9797. SUPPLEMENTARY INFORMATION: Executive Summary: Purpose: On September 16, 2011, the AIA was enacted into law (Pub. L. 112-29, 125 Stat. 284 (2011)). -
Assessment of the Covered Business Method Patent Review Program
United States Government Accountability Office Report to the Chairman, Committee on the Judiciary, House of Representatives March 2018 U.S. PATENT AND TRADEMARK OFFICE Assessment of the Covered Business Method Patent Review Program GAO-18-320 March 2018 U.S. PATENT AND TRADEMARK OFFICE Assessment of the Covered Business Method Patent Review Program Highlights of GAO-18-320, a report to the Chairman, Committee on the Judiciary, House of Representatives Why GAO Did This Study What GAO Found Patents can promote innovation by From September 2012 through September 2017, entities facing patent giving inventors exclusive rights to their infringement lawsuits filed 524 petitions challenging the validity of 359 patents inventions, and patent owners can under the U.S. Patent and Trademark Office’s (USPTO) covered business bring infringement lawsuits against method (CBM) program, resulting in decisions against about one-third of these anyone who uses, makes, sells, offers patents. The CBM program provides entities facing infringement lawsuits an to sell, or imports a patented invention opportunity to challenge the validity of a business method patent by without authorization. As GAO demonstrating that it did not meet requirements for patentability. Business previously reported, such lawsuits can method patents focus on ways of doing business in areas such as banking or e- take years and cost several million commerce. The rate of filing petitions over this period has fluctuated but has dollars. USPTO’s CBM program generally declined since 2015, and none were filed in August or September provides a trial proceeding to challenge a patent’s validity at USPTO’s board 2017.